Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hideki Enokida

Showing results (151-160 of 177) with videos related to

Pageof 18
Sort By:
Plos One|April 28, 2022
Effects of immune checkpoint inhibitor therapy resumption in patients with malignant tumors after moderate-to-severe immune-related adverse eventsMachiko Kawahira, Shuji Kanmura, Keiko Mizuno, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 16, 2026
Circulating Tumor DNA Genomic Profiling in <sup>223</sup>Ra-Treated Metastatic Castration-Resistant Prostate Cancer: The KYUCOG-1901 StudyMasaki Shiota, Maki Fujiwara, Takayuki Sumiyoshi, et al.
Cancer Research|September 3, 2004
CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancerHideki Enokida, Hiroaki Shiina, Mikio Igawa, et al.
European Urology Open Science|July 11, 2022
Enzalutamide Versus Abiraterone plus Prednisolone Before Chemotherapy for Castration-resistant Prostate Cancer: A Multicenter Randomized Controlled TrialKouji Izumi, Takashi Shima, Koji Mita, et al.
Journal of Clinical Medicine|June 24, 2022
Serum IgG4 Concentration Is a Potential Predictive Biomarker in Glucocorticoid Treatment for Idiopathic Retroperitoneal FibrosisShoichiro Mukai, Naotaka Sakamoto, Hiroaki Kakinoki, et al.
The Prostate|September 20, 2024
Dose modification in enzalutamide and abiraterone plus prednisolone for castration-resistant prostate cancer: A subanalysis from the ENABLE study for PCaNobumichi Tanaka, Kouji Izumi, Yasushi Nakai, et al.
The Prostate|April 4, 2025
Efficacy and Safety of Enzalutamide and Abiraterone Plus Prednisolone in Elder Castration-Resistant Prostate Cancer Patients: A Sub-Analysis From the ENABLE StudyTakehiko Okamura, Kouji Izumi, Satoshi Kurokawa, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|January 9, 2024
Clinicopathological characteristics of adrenocortical carcinoma in the Kyushu-Okinawa area of JapanShotaro Nakanishi, Yumi Fukushima, Junichi Inokuchi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2006
Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/beta-catenin signaling pathwayShinji Urakami, Hiroaki Shiina, Hideki Enokida, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|February 2, 2026
Clinical Outcomes and Clinicopathological Features of Primary Urethral Carcinoma: A Multicenter Retrospective Study in JapanKeita Kobayashi, Kei Daizumoto, Takuya Tsujino, et al.
Pageof 18

Showing results (151-160 of 177) with videos related to

Sort By:
Pageof 18
Plos One|April 28, 2022
Effects of immune checkpoint inhibitor therapy resumption in patients with malignant tumors after moderate-to-severe immune-related adverse eventsMachiko Kawahira, Shuji Kanmura, Keiko Mizuno, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 16, 2026
Circulating Tumor DNA Genomic Profiling in <sup>223</sup>Ra-Treated Metastatic Castration-Resistant Prostate Cancer: The KYUCOG-1901 StudyMasaki Shiota, Maki Fujiwara, Takayuki Sumiyoshi, et al.
Cancer Research|September 3, 2004
CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancerHideki Enokida, Hiroaki Shiina, Mikio Igawa, et al.
European Urology Open Science|July 11, 2022
Enzalutamide Versus Abiraterone plus Prednisolone Before Chemotherapy for Castration-resistant Prostate Cancer: A Multicenter Randomized Controlled TrialKouji Izumi, Takashi Shima, Koji Mita, et al.
Journal of Clinical Medicine|June 24, 2022
Serum IgG4 Concentration Is a Potential Predictive Biomarker in Glucocorticoid Treatment for Idiopathic Retroperitoneal FibrosisShoichiro Mukai, Naotaka Sakamoto, Hiroaki Kakinoki, et al.
The Prostate|September 20, 2024
Dose modification in enzalutamide and abiraterone plus prednisolone for castration-resistant prostate cancer: A subanalysis from the ENABLE study for PCaNobumichi Tanaka, Kouji Izumi, Yasushi Nakai, et al.
The Prostate|April 4, 2025
Efficacy and Safety of Enzalutamide and Abiraterone Plus Prednisolone in Elder Castration-Resistant Prostate Cancer Patients: A Sub-Analysis From the ENABLE StudyTakehiko Okamura, Kouji Izumi, Satoshi Kurokawa, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|January 9, 2024
Clinicopathological characteristics of adrenocortical carcinoma in the Kyushu-Okinawa area of JapanShotaro Nakanishi, Yumi Fukushima, Junichi Inokuchi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2006
Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/beta-catenin signaling pathwayShinji Urakami, Hiroaki Shiina, Hideki Enokida, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|February 2, 2026
Clinical Outcomes and Clinicopathological Features of Primary Urethral Carcinoma: A Multicenter Retrospective Study in JapanKeita Kobayashi, Kei Daizumoto, Takuya Tsujino, et al.
Pageof 18